Cargando…

Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease

Fibrosing chronic graft-versus-host disease (cGVHD) is a debilitating complication of allogeneic stem cell transplantation (alloSCT). A driver of fibrosis is the kynurenine (Kyn) pathway, and Kyn metabolism patterns and cytokines may influence cGVHD severity and manifestation (fibrosing versus gastr...

Descripción completa

Detalles Bibliográficos
Autores principales: Orsatti, Laura, Stiehl, Thomas, Dischinger, Katharina, Speziale, Roberto, Di Pasquale, Pamela, Monteagudo, Edith, Müller-Tidow, Carsten, Radujkovic, Aleksandar, Dreger, Peter, Luft, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561165/
https://www.ncbi.nlm.nih.gov/pubmed/34755129
http://dx.doi.org/10.1016/j.xcrm.2021.100409
_version_ 1784593073810964480
author Orsatti, Laura
Stiehl, Thomas
Dischinger, Katharina
Speziale, Roberto
Di Pasquale, Pamela
Monteagudo, Edith
Müller-Tidow, Carsten
Radujkovic, Aleksandar
Dreger, Peter
Luft, Thomas
author_facet Orsatti, Laura
Stiehl, Thomas
Dischinger, Katharina
Speziale, Roberto
Di Pasquale, Pamela
Monteagudo, Edith
Müller-Tidow, Carsten
Radujkovic, Aleksandar
Dreger, Peter
Luft, Thomas
author_sort Orsatti, Laura
collection PubMed
description Fibrosing chronic graft-versus-host disease (cGVHD) is a debilitating complication of allogeneic stem cell transplantation (alloSCT). A driver of fibrosis is the kynurenine (Kyn) pathway, and Kyn metabolism patterns and cytokines may influence cGVHD severity and manifestation (fibrosing versus gastrointestinal [GI] cGVHD). Using a liquid chromatography-tandem mass spectrometry approach on sera obtained from 425 patients with allografts, we identified high CXCL9, high indoleamine-2,3-dioxygenase (IDO) activity, and an activated Kyn pathway as common characteristics in all cGVHD subtypes. Specific Kyn metabolism patterns could be identified for non-severe cGVHD, severe GI cGVHD, and fibrosing cGVHD, respectively. Specifically, fibrosing cGVHD was associated with a distinct pathway shift toward anthranilic and kynurenic acid, correlating with reduced activity of the vitamin-B2-dependent kynurenine monooxygenase, low vitamin B6, and increased interleukin-18. The Kyn metabolite signature is a candidate biomarker for severe fibrosing cGVHD and provides a rationale for translational trials on prophylactic vitamin B2/B6 supplementation for cGVHD prevention.
format Online
Article
Text
id pubmed-8561165
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85611652021-11-08 Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease Orsatti, Laura Stiehl, Thomas Dischinger, Katharina Speziale, Roberto Di Pasquale, Pamela Monteagudo, Edith Müller-Tidow, Carsten Radujkovic, Aleksandar Dreger, Peter Luft, Thomas Cell Rep Med Article Fibrosing chronic graft-versus-host disease (cGVHD) is a debilitating complication of allogeneic stem cell transplantation (alloSCT). A driver of fibrosis is the kynurenine (Kyn) pathway, and Kyn metabolism patterns and cytokines may influence cGVHD severity and manifestation (fibrosing versus gastrointestinal [GI] cGVHD). Using a liquid chromatography-tandem mass spectrometry approach on sera obtained from 425 patients with allografts, we identified high CXCL9, high indoleamine-2,3-dioxygenase (IDO) activity, and an activated Kyn pathway as common characteristics in all cGVHD subtypes. Specific Kyn metabolism patterns could be identified for non-severe cGVHD, severe GI cGVHD, and fibrosing cGVHD, respectively. Specifically, fibrosing cGVHD was associated with a distinct pathway shift toward anthranilic and kynurenic acid, correlating with reduced activity of the vitamin-B2-dependent kynurenine monooxygenase, low vitamin B6, and increased interleukin-18. The Kyn metabolite signature is a candidate biomarker for severe fibrosing cGVHD and provides a rationale for translational trials on prophylactic vitamin B2/B6 supplementation for cGVHD prevention. Elsevier 2021-10-19 /pmc/articles/PMC8561165/ /pubmed/34755129 http://dx.doi.org/10.1016/j.xcrm.2021.100409 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Orsatti, Laura
Stiehl, Thomas
Dischinger, Katharina
Speziale, Roberto
Di Pasquale, Pamela
Monteagudo, Edith
Müller-Tidow, Carsten
Radujkovic, Aleksandar
Dreger, Peter
Luft, Thomas
Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
title Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
title_full Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
title_fullStr Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
title_full_unstemmed Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
title_short Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
title_sort kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561165/
https://www.ncbi.nlm.nih.gov/pubmed/34755129
http://dx.doi.org/10.1016/j.xcrm.2021.100409
work_keys_str_mv AT orsattilaura kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT stiehlthomas kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT dischingerkatharina kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT spezialeroberto kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT dipasqualepamela kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT monteagudoedith kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT mullertidowcarsten kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT radujkovicaleksandar kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT dregerpeter kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease
AT luftthomas kynureninepathwayactivationanddeviationtoanthranilicandkynurenicacidinfibrosingchronicgraftversushostdisease